NT-pro-BNP IN DIABETES MELLITUS
Kamakhya Kumar¹, Arunima Datta², Pramod Kumar³, Anant Kumar⁴, Arup Bandyopadhyay⁵

HOW TO CITE THIS ARTICLE:
Kamakhya Kumar, Arunima Datta, Pramod Kumar, Anant Kumar, Arup Bandyopadhyay. "NT-pro-BNP in Diabetes Mellitus". Journal of Evolution of Medical and Dental Sciences 2015; Vol. 4, Issue 50, June 22; Page: 8654-8660, DOI: 10.14260/jemds/2015/1252

ABSTRACT: BACKGROUND: Brain natriuretic peptide (BNP) is a peptide hormone that is synthesized largely by the heart in the form of pre-pro-BNP which is cleaved to pro-BNP, and then proteolyzed to BNP and NT-pro-BNP. ANP, BNP and NT-pro-BNP are sensitive diagnostic markers for heart failure. NT-pro-BNP being more sensitive is preferable to BNP and ANP for the detection of heart failure. Several studies have shown that NT-pro-BNP level is higher in diabetics. We have here tried to study the same dividing the diabetic population duration-wise. MATERIALS AND METHODS: Patients with uncomplicated diabetes mellitus aged below 50 years were selected irrespective of sex. Patients without diabetes mellitus were taken as controls (Group A). Others viz., Group B consists of DM patients suffering from diabetes mellitus for a period <1 year, Group C consists of DM patients suffering for a period >2 year but <6 years and Group D comprises patients of uncomplicated DM for a period >10 years. NT-pro-BNP values in plasma are determined by AQT 90 FLEX NT-pro BNP Assay. Blood samples are collected with EDTA as anti-coagulant and plasma is separated. A Roche Modular Analytics E170 immuno assay analyser was used. RESULTS: The results show that the plasma NT-pro-BNP becomes progressively higher in diabetic patients with increased duration of diabetes when compared to the normal healthy controls. The difference in plasma NT-pro-BNP levels of Groups A and D showed a high degree of statistical significance but the difference was not statistically significant in case of Group B and Group C. CONCLUSION: It was found that uncomplicated DM patients of short and moderate duration had greater plasma NT-pro-BNP levels than the age matched non-diabetic healthy group though the difference is not significant. However the levels of NT-pro-BNP in patients of Group D were even higher than Group B and C (Gr A vs. Gr D: p<0.005). Diabetic patients can be periodically checked for NT-pro BNP to detect early onset Diabetic cardiomyopathy or other cardiac disorders as suggested by high NT-pro-BNP levels.

KEYWORDS: NT-pro-BNP; Diabetic Cardiomyopathy, Diabetes Mellitus.

INTRODUCTION: Cardiomyopathy as per recent definition of the World Health Organization is ventricular dysfunction due to inability to correct volume or pressure overload in valvular diseases, hypertension, coronary artery disease (CAD), Diabetes Mellitus (DM), alcoholism, viral myocarditis and genetic preponderance etc.¹ DM is a not so uncommon cause of cardiomyopathy when the former is particularly long standing and both are becoming increasingly more common. Since NT-pro-BNP and other natriuretic cardiac markers are enhanced in cardiac ailments as noted above, it will not be unreasonable to study NT-pro-BNP levels in diabetic patients particularly when cardiomyopathy is suspected to be setting in.

NT-pro-BNP belongs to the natriuretic peptide (NP) family of hormones which contribute to the control of body fluid homeostasis and blood pressure regulation through their combined actions on vasculature, kidneys, and adrenal glands.² The best-known members of these families are ANP,³ BNP,⁴ NT-pro-ANP, NT pro-BNP⁵,⁶ and C-type natriuretic peptide (CNP).⁷ ANP and BNP are produced predominantly by the cardiac atrium and ventricle respectively in response to increased atrial and
ventricular transmural pressure, although BNP was first isolated from brain. These two natriuretic peptides have pronounced hypotensive, diuretic and natriuretic effects. BNP was first identified in the brain, in the form of pre-pro-BNP which is cleaved to pro-BNP. Proteolysis of pro-BNP (108 amino acids) results in BNP (32 amino acids) and the N-terminal piece of pro-BNP (NT-pro-BNP: 76 amino acids). Both BNP and NT-pro-BNP are sensitive diagnostic markers for heart failure along with Atrial Natriuretic Peptide (ANP).

BNP and NT-pro-BNP are better markers than ANP. Again, NT-pro-BNP is even preferable to BNP for the detection of heart failure and dilated cardiomyopathy, particularly in asymptomatic patients, as the NT-pro-BNP is more sensitive than BNP.

Plasma levels of ANP and BNP are markedly elevated in heart failure and after acute myocardial infarction (AMI), and are powerful predictors of ventricular dysfunction and mortality. Moreover, within heart tissue gene expression of both ANP and BNP is reportedly unregulated in animal models of MI and heart failure and human heart disease. Although ANP is expressed primarily in the atria in adults, the ventricle is the major site of ANP and BNP expression in embryos.

The mechanism of natriuretic peptide expression is very characteristic. The cellular response to cardiac injury is initiated by an invasion of inflammatory cells, followed by infiltration by endothelial cells and fibroblasts to form granulation tissues. A complex interplay of paracrine factors released by macrophages and injured myositis triggers the phenotypic switch of fibroblasts to myofibroblasts, which deposit collagen to form the fibrotic scar. Changes at the site of injuries are accompanied by on-going hypertrophy and remodelling of the non-infracted myocardium. ANP and BNP are synthesised by cardiac myofibroblast. Cardiac fibroblasts express all three NP receptors and can generate the second messenger cGMP in response to both ANP and BNP. ANP inhibits the DNA synthesis and proliferation of cardiac fibroblast in culture. It also inhibits the synthesis of collagen by rat and human cardiac fibroblast via cGMP. During regional mechanical stress and hemodynamic overload to the left ventricle there is marked increase in mRNA related to both ANP and BNP.

NT-pro-BNP is a marker for functional cardiac impairment and is increased in heart disease with or without symptoms. It is a hormonally active natriuretic peptide i.e., mainly released from cardiomyocytes in left ventricular wall in reaction to stretch and tension of the myocardial wall. The prohormone pro-BNP splits into BNP and the hormonally inactive remnant NT-pro-BNP by proteolytic cleavage. Therefore NT-pro-BNP is not hormonally active but a good marker of heart disease. The half-life of NT-pro-BNP in circulation is around 120 minutes. The normal range for circulating NT-pro-BNP is 100pg/ml.

Diabetic cardiomyopathy is a not so uncommon clinical condition. It is a measurable deterioration of myocardial ability to contract due to any reason usually leading to heart failure. Common symptoms include dyspnoea and peripheral oedema and these patients are often at risks of dangerous forms of arrhythmia and sudden cardiac death.

The term cardiomyopathy came into use only 50 years ago. In 2008, the European society of cardiology (ESC) defined it as a myocardial disorder in which the heart muscle is structurally and functionally abnormal. Since cardiomyopathy is a dangerous and often fatal disease an early diagnosis of cardiomyopathy in the natural history of DM is crucial. Periodic estimation of plasma NT-pro-BNP will be a valuable tool for this.
MATERIALS AND METHODS: The study was done in four groups of patients: Group A, Group B, Group C and Group D. Group A consists of perfectly healthy volunteers below the age of 50 years belonging to both sexes and free from any cardiac or liver disease or DM. Group B consists of DM patients without any complications particularly cardiac or hepatic, suffering from diabetes mellitus for a period <1 year. Group C consists of DM patients who are proven patients of DM for a period >2 year but <6 years. Group D comprises patients of DM for a period of >10 years. 30 subjects are selected for each of Group A and Group B, but Group C contains 11 subjects and Group D contains 17 subjects as we could not get more number of subjects with established and proven diabetes mellitus suffering from the ailment for such a prolonged period without developing any complications particularly cardiac and hepatic, in our set up. History and clinical profile of all the patients of all the four groups are taken first. All the patients were also subjected to skiagram of chest (PA view), ECG, echocardiography with colour Doppler studies, USG (Whole abdomen) and liver function tests.

Patients aged above 50 years are deliberately excluded because NT-pro-BNP level becomes higher and higher even in otherwise healthy non-diabetic old persons as their age progresses. Diabetic patients with other disorders like cirrhosis of liver congestive cardiac failure are also excluded because they also show high plasma NT-pro BNP levels. The NT-pro-BNP level cut off value is taken as 100pg/ml. Institutional ethical committee approval and patient’s written consent were taken.

NT-pro-BNP values in plasma are determined by AQT 90 FLEX NT-pro BNP Assay. Blood samples are collected by venepuncture with EDTA as anti-coagulate and from that plasma is separated. A Roche Modular Analytics E170 immune assay analyser was used. Data for statistical analysis were expressed as (mean±SD) and statistical significance were computed by “Unpaired t-test”. The level of significance was fixed at 5% (p<0.05). The statistical analysis was done using software SPSS 16 version.

RESULTS: The results of our studies are given in following Tables 1 & 2:

| Group | Group A | Group B | Group C | Group D |
|-------|---------|---------|---------|---------|
| Type  | Controls| Diabetic Duration<1yr | Diabetic Duration >2yr-<6yrs | Diabetic Duration >10yrs |
| NT-pro-BNP Level (pg/ml) Mean±SD | 49.47±18.86 | 102.47±21.97 | 258.71±139.96 | 342.73±101.33 |

**TABLE 1:** Comparison of NT-pro-BNP Level (pg/ml) (mean±SD) in Groups A, B, C & D

| Comparison between | Group A & Group B | Group A & Group C | Group A & Group D |
|--------------------|------------------|------------------|------------------|
| t-value            | 1.413            | 0.0001469        | 6.02055          |
| p-value            | >0.05            | >0.05            | <0.005           |
| Level of significance | Not significant | Not significant | Highly significant |

**TABLE 2:** Comparison of level of significance in Group A, B, C & D
The results show that the plasma NT-pro-BNP becomes progressively higher compared to the normal healthy controls (Group A) in short duration DM (Group B), moderate duration DM (Group C) and long duration DM (Group D) respectively. Although short duration diabetics without complications have higher plasma NT-pro-BNP levels than healthy controls but the difference is not statistically significant. The plasma NT-pro-BNP difference between non-diabetic controls and long duration diabetics however shows a high degree of statistical significance (<0.005).

**DISCUSSION:** It was found in our experiments that the plasma NT-pro-BNP level is higher in short and moderate duration diabetics than in non-diabetic healthy controls. However this difference is not statistically significant. Again when the plasma NT-pro-BNP level of the controls and compared with patients of long duration diabetics the difference becomes statistically highly significant.

The concept that there may be a direct relation between diabetes and heart failure and cardiomyopathy is not new. In 1954, Lundbaek published an article on clinically important complications in patients with diabetes underlining that heart disease was common in patients with DM and was present in two-thirds of elderly diabetic subjects. He was the first to suggest the presence of a diabetes specific cardiomyopathy. Currently, IHD is the leading cause of CHF in Industrialized society with diabetes as a rapidly emerging risk factor. Considering the rapidly growing prevalence of diabetes this means that the combination of diabetes and CHF will become increasingly more common in the future.

In our study the plasma NT-pro-BNP level was definitely higher in short and moderate duration diabetics than that in normal controls but the difference was not statistically significant. Another study in which NT-pro-BNP levels are shown to be significantly elevated in cohort of patients with diabetes, but the duration of diabetes was not considered. Charlotte et al had convincingly demonstrated earlier a similar finding and suggested NT-pro-BNP as a screening marker as increased risk predictor of CVD in diabetes giving a strong base to our study, but in their study also the diabetic population was not divided in groups according to duration of the disease. There are several possible explanations for elevated NT-pro-BNP levels in patients with diabetes as they have a higher prevalence of diastolic dysfunction, more peripheral and distal atherosclerotic changes in the coronary tree due to increased blood lipids. Hearts from patients with diabetes have increased collagen content as have been verified in autopsy studies and it is proposed that natriuretic peptide synthesis increases by the same mechanism that transform cardiac fibroblast into a collagen-secreting cell. Another possible mechanism working from the very start of diabetes could be decreased relaxation because of ATP deficiency.

The intracellular glucose deficiency among patients with diabetes leads to a higher use of free fatty acids through beta oxidation in the myocardium. A sufficient amount of carbohydrate break down is of great importance for assuming an adequate function of the ion pumps meaning Na⁺/K⁺-ATPase and Ca²⁺ ATPase, which maintains the right cardiomyocyte membrane potential and intracellular Ca²⁺ transport, that triggers relaxation. In the diabetes heart, this balance is disturbed, proposing a functional explanation to the impaired relaxation in the myocardium. Thus, NT-pro-BNP might be especially useful for screening CVD risks in diabetes subjects.

**CONCLUSION:** Our studies have shown that in established diabetes mellitus of moderate to long duration the plasma NT-pro-BNP level is much higher than that in uncomplicated non-diabetic population and the difference is statistically highly significant.
This suggests that at the beginning in uncomplicated state the plasma NT-pro-BNP level is slightly higher than normal keeps on increasing as cardiomyopathy or any gross cardiac disease for that matter gradually sets in and its severity increases. Therefore, measurement of NT-pro-BNP might be a simple but useful screening tool for early diagnosis of CVD in diabetics. However, more elaborate studies are needed to confirm the findings of this small study.

ACKNOWLEDGEMENT: We gratefully acknowledge the assistance of all the faculty members, post graduate students and staffs of physiology department for their exquisite suggestions.

REFERENCES:
1. Richardson P. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathy. Circulation. 1996; 93: 341-2.
2. Espiner EA., Richards AM., Yandle TG., Nicholls MG. Natriuretic hormones. Endocrinol Metab Clin North Am. 1995; 24: 481-509.
3. De Bold AJ., Borenstein HB., Veress AT., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats Life Sci. 1981; 28: 89-94.
4. Sudoh T., Minamino N., Kangawa K., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988; 332: 78-81.
5. Bhalla V., Willis S., Maisel AS. B-type natriuretic peptide: the level and the drug partners in the diagnosis of congestive heart failure. Congest Heart Fail. 2004; 10 (1 suppl 1): 3-27.
6. Atisha D., Bhalla MA., Morrison LK., Felicio L., Clopton P., Gaerdetto N., Kazanegra R., Chui A., Maisel AS. A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction. 2004; Am Heart J 148: 518-23.
7. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990; 168: 863-870.
8. Mukoyama M., Nakao K., Obata K., Jougasaki M., Yoshimura M., Morita E., Hosoda K., Suga S., Ogawa Y., Yaue H., Imura H Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun. 1991; 180: 431-436.
9. Foy S., Crozier I., Richards A., Nicholls M., Turner J., Frampton C., Ikram H. Neurohumoral changes after acute myocardial infarction. Relationships with hemodynamic indices and effects of ACE inhibitors. Eur Heart J. 1995; 16: 770-78.
10. Lainchbury J., Espiner E., Frampton C., Richards A., Yandle T., Nicholls M. Cardiac Natriuretic Peptides as predictors of mortality. J Intern Med. 1997; 241: 257-59.
11. Ama N., Etoh H., Shirakami G. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. (1995); 92: 1558-64.
12. Luchner A., Stevens T., Borgeson D. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 1998; 274: H1684-H1699.
13. Perrella M., Schwab T., O’Murchu B. Cardiac atrial natriuretic factor during evolution of congestive heart failure. Am J Physiol. 1992; 262: H1248-H1255.
14. Shimoike H., Iwai N., Kinoshita M. Differential regulation of natriuretic peptide genes in infarcted rat hearts. Clin Exp Pharmacol Physiol. 1997; 24: 23-30.
15. Saito Y., Nakao K., Arai H. Augmented expression of atrial natriuretic poly peptide gene in ventricle of human failing heart. J Clin Invest. 1989; 83: 298-305.
16. Hosoda K., Nakao K., Mudyama M. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension. 1991; 17: 1152-56.
17. Cameron VA., Aitken GD., Ellmers LJ. The sites of gene expression of atrial brain, and C-type natriuretic peptide in mouse foetal development: temporal changes in embryos and placenta. Endocrinology. 1996; 137: 817-24.
18. Weber K., Sun Y., Katwa L. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol. 1997; 29: 31-42.
19. Lin X., Hanze. J, Heese F. Gene expression of Natriuretic peptide receptors in myocardial cells. Circ Res. 1995; 77: 750-8.
20. Fujisaki H., Itoe H., Hirata Y. Natriuretic peptides inhibit angiotensin II induced proliferation of rat cardiac fibroblasts by blocking endothelin I gene expression. J Clin Invest. 1995; 96: 1059-65.
21. Caw L., Gardner D. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995; 25: 227-34.
22. Redondo J., Bishop J., Wilkins M. Effect of Atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblast. Br J Pharmacol. 1998; 124: 1455-62.
23. Bilder G., Sweet C., Emmert S., Schofield T., Medina R., Stabilito I., Friedman P. Cardiac and non-cardiac atrial natriuretic factor (ANF) biosynthesis and storage and plasma ANF in the rat model of chronic ventricular dysfunction. Endocrinology. 1989; 124: 1515-21.
24. Puschendorf B., Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab. 2001; 47: 265-67.
25. Pfister R, Schneider CA. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta. 2004; 349: 25-38.
26. Brune K., Katus Ha., Moecks J., Spanuth E., Jaffe AS., Giannitsis E. The concentration of N-terminal pro-B-type Natriuretic peptide predicts the list of cardiovascular adverse events from anti-inflammatory drugs: A pilot trial. Clin Chem. 2008; 54: 1149-57.
27. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J. Dec 1980; 44 (6): 672-73.
28. Lundbaek K. Diabetic angiopathy: a specific vascular disease. Lancet. 1954; 263: 377-79.
29. Lundbaek K. Is there a diabetic cardiopathy? In: Schettler G, ed. Pathogenetische Faktoren des Myokardinfarkts. Stuttgart; Schattauer, 1969: 63-71.
30. Massei BM., Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997; 133: 703-712.
31. Solang L., Malmberg K., Ryden L. Diabetes mellitus and congestive heart failure. Eur Heart J. 1999; 20: 789-95.
32. King H., Aubert RE., Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates and projections. Diabetes Care. 1998; 21: 1414-31.
33. Sahu A., Gupta T, Kavishwar A., DeySarkar P., Sing RK. Diagnostic role of NT-pro-BNP in diabetes type2 patients associated with cardiovascular disease risk, a study from central India. J Medicine. 2010; 11: 33-8.
34. Charlotte K., Ida G., Torjorn O., et al. Prognostic value of NH₂-Terminal pro B-type Natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care. 2006; 29: 1411-13.
35. Butler R., MacDonald TM., Struthers AD., Morris AD. The clinical implications of diabetic heart disease. Eur Heart J. 1998; 19: 1617-27.
36. Young ME., McNulty P., Taegtmeyer H., Adaptation and maladaptation of the heart in diabetes. Potential mechanism. Circulation. 2002; 105: 1861-70.
37. Braunwald E., Bristow MR. Congestive cardiac failure: 50 years of progress. Circulation 2000; 102: IV14-IV23.
38. King LM., Opie LH. Glucose delivery is a major determinant of glucose utilization in the ischaemic myocardium with a residual flow. Cardiovasc Res 1998; 39: 381-92.

AUTHORS:
1. Kamakhya Kumar
2. Arunima Datta
3. Pramod Kumar
4. Anant Kumar
5. Arup Bandyopadhyay

PARTICULARS OF CONTRIBUTORS:
1. Associate Professor, Department of Physiology, MGM Medical College & LSK Hospital, Kishanganj.
2. Post Graduate Student, Department of Physiology, MGM Medical College & LSK Hospital, Kishanganj.
3. Post Graduate Student, Department of Physiology, MGM Medical College & LSK Hospital, Kishanganj.

FINANCIAL OR OTHER COMPETING INTERESTS: None

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Arup Bandyopadhyay,
Professor & HOD, Department of Physiology,
MGM Medical College & LSK Hospital,
Kishanganj-855107, Bihar.
E-mail: arupbanerjee1953@gmail.com

Date of Submission: 27/05/2015.
Date of Peer Review: 28/05/2015.
Date of Acceptance: 13/06/2015.
Date of Publishing: 19/06/2015.